Northpond Ventures
Venture capitalBethesda · Seed–Series A · 37 people tracked
Also known as NORTHPOND VENTURES, LLC
Investment thesis
Embeds multi‑year research programs at top institutions, co‑runs labs and project selection, then converts academic IP into startups through negotiation, incorporation and syndication; focuses on tools, platforms and biomanufacturing.
Source: firm website, verified Aug 25, 2026.
Team · 37 people
from the firm's website & public directories
What they invest in
from 20 of 24 portfolio companiesBiotech ×15AI & Machine Learning ×10Healthtech ×9Medical Devices ×8Deep Tech ×6Digital Health ×5Hardware ×2SaaS ×2
HQs:United States×21
Investments · 24 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 22022 · 12020 · 12019 · 32018 · 111 dated
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)Kevin Knopp(Executive Officer, Director)Joseph Griffith IV(Executive Officer)
BoardKevin Hrusovsky(Director)Corey Steffek(Director)
Board seatSharon Kedar· per SEC Form D · $17.5M raise · filed Apr 2019
Co-investorsARCH Venture PartnersRazor's Edge VenturesUTECAramco Ventures
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Robert Carson(Executive Officer, Director)Rob Carson(Chief Executive Officer)in
Board seatSharon Kedar· per SEC Form D
Co-investorsARCH Venture Partners6 Dimensions CapitalApplied VenturesKilonova CapitalPura Vida InvestmentsRazor's Edge Ventures+2 more
Inflammatix develops host-response-based molecular diagnostics tests to identify acute infections and sepsis in emergency and critical care settings.
AI & Machine LearningBiotechHealthtechMedical DevicesBurlingame, US
Tim Sweeney(Co-Founder and CEO)Purvesh Khatri(Co-Founder and Chief Scientist)JONATHAN ROMANOWSKY(Executive Officer)
BoardKENNETH BAHK(Director)MICHAEL RUBIN(Director)DAVID PERSING(Director)
Co-investorsKhosla VenturesOSF VenturesDFJ
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.
AI & Machine LearningBiotechHealthtech
Susan Hill(Founder & Chief Executive Officer)Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)
Co-investorsGV (Google Ventures)ForbionJohnson & Johnson Innovation – JJDCSV Health Investors
Octave develops blood-based biomarker tests for neurodegenerative diseases including multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
AI & Machine LearningBiotechDigital HealthMedical DevicesMenlo Park, US
William Hagstrom(Founder and Chairman)Doug Biehn(President and CEO)
Co-investorsSandbox IndustriesSection 32Blue Venture FundsEcho Health VenturesHikma VenturesGreycroft+1 more
Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.
AI & Machine LearningBiotechDeep TechCambridge, US
Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)G. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)Stephanie Torruella(Executive Officer)Preet Makkar(Executive Officer)
Co-investorsLifeforce CapitalMagnetic VenturesTaiho Ventures, LLCDolby Family Ventures
VitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics.
BiotechDigital HealthMedical Devices
Vasu Nadella(Founder)in
Co-investorsNext VenturesInovia CapitalLachy GroomMarc BenioffSam Altman1955 Capital+6 more
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)Jiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)Robert Carson(Executive Officer, Director)Terry Lo(Director)Seth Benson(Executive Officer)Simona Levi(Executive Officer)
Co-investorsARCH Venture PartnersM VenturesNovalis LifeSciences
Boston, US
Board seatSharon Kedar· per SEC Form D · $20M raise · filed Mar 2020
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications.
BiotechDeep TechWatertown, US
Daniel Ahlstedt(Executive Officer, Director)Jonathan Rittichier(Founder)in
BoardAndrew Lee(Director)inSteven Kasok(Director)
Board seatPaxton Major· per SEC Form D
Co-investorsBreakout VenturesCoatue Management
BiotechNew Haven, US
Rong Fan(Director)Sean McKay(Executive Officer, Director)Sean Mackay(Executive Officer, Director)
BoardDaniel Wagner(Director)John Conley(Director)Gregory Ho(Director)
Board seatSharon Kedar· per SEC Form D · $85M raise · filed Jan 2021
Cambridge, US
Clinton Hansen(Executive Officer, Promoter)Wesley Wong(Executive Officer, Director, Promoter)
Board seatSteve LiapisElias Quijano· per SEC Form D · $15M raise · filed Sep 2025
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)Gregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)Axel Scherer(Director)
BoardJustin Klein(Director)in
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Associates+2 more
Culture Biosciences provides software and bioreactor hardware solutions for bioprocess development, enabling researchers to design, monitor, and analyze experiments remotely with cloud-native analytics and AI/ML insights.
AI & Machine LearningBiotechCloud ComputingHealthtechSan Francisco, US
Will Patrick(Founder/CEO)inMatt Ball(Founder/CTO)in
Co-investorsCompoundDCVC (Data Collective)GRIDS CapitalHemisphere Ventures LLCThe E14 FundY Combinator+4 more
Eleanor Health is an outpatient addiction treatment program that delivers remote evidence-based care for substance use disorder, including medication-assisted treatment and counseling.
Digital HealthHealthtechMental HealthWaltham, US
Dr. Nzinga Harrison(Chief Medical Officer and Co-founder)Corbin Petro(Executive Officer, Director)Srishti Mirchandani(Executive Officer)
BoardDavid Whelan(Director)inSonny Goyal(Director)Kurt Sheline(Director)in
Co-investorsEcho Health VenturesRethink ImpactGeneral CatalystTown Hall VenturesWarburg Pincus
Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.
BiotechDigital HealthHealthtechMedical DevicesMadison, US
Jonathan Oliner(Executive Officer)inManeesh K. Arora(Executive Officer, Director, Promoter)Maneesh Arora(Founder)inMichelle B. Arora(Director)Terrence P. Brady(Executive Officer)
Co-investorsARCH Venture PartnersSands Capital Ventures
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsARCH Venture PartnersDecheng CapitalAlexandriaDeerfield Management CompanyGV (Google Ventures)Nan Fung Life Sciences
BiotechPortola Valley, US
Lena Wu(Executive Officer, Director)Erik Gentalen(Director)Michael Rubin(Director)
BoardJenny Rooke(Director)in
Co-investorsVertical Venture PartnersGenoa Ventures
Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.
BiotechDeep TechHardwareCambridge, US
Cullen Buie(Director)Paulo Garcia(Executive Officer, Director, Promoter)Michael Chiu(Director, Executive Officer)
BoardPaxton Major(Director)Ann DeWitt(Director)inPaul Wotton(Director)
Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+1 more
Outcomes4Me is an AI-driven patient platform that integrates with NCCN clinical oncology guidelines to provide personalized cancer care guidance, treatment options, clinical trial recommendations, and genetic testing information.
AI & Machine LearningDigital HealthHealthtechCambridge, US
Maya R. Said(Founder and CEO)Osama Rahma(Founder)
BoardAndrea Jackson(Director)inDavid Fleshman(Director)David Auckland(Director)
Co-investorsAsset Management CompanyHealthX VenturesSierra Ventures
Scitara provides cloud-based integration and data management software for scientific laboratories, enabling connection of lab instruments and applications into a unified environment with AI-powered analytics.
AI & Machine LearningBiotechData & InfrastructureSaaSMarlborough, US
Ajit Nagral(CEO & Chairman)Geoff Gerhardt(Executive Officer, Promoter)Vinayak Purohit(Executive Officer)
BoardCharles M. Hazard, Jr.(Director)Andrea Jackson(Director)inRohit Khanna(Director)
Co-investorsFlybridge Capital Partners
Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.
Emeryville, US
Jeffrey Kim(Executive Officer, Director)Jeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)
BoardCorey Ritter(Director)in
Co-investorsARCH Venture PartnersAnterra Capital
AgTechEmeryville, US
Eric Davidson(Director)Travis Bayer(Director)Paul Beck(Executive Officer)Dave Vosburg(Executive Officer)Adam Litle(Executive Officer, Director)Derek Norman(Director)
Co-investorsCavallo VenturesCultivian Sandbox VenturesS2G InvestmentsFall Line CapitalFootPrint CoalitionLeaps by Bayer+2 more
Uptime Health provides operational tools and preventive maintenance plans to healthcare practices to reduce downtime and ensure regulatory compliance.
Enterprise SoftwareHealthtechSaaSBoston, US
William Olsen(Executive Officer, Director)Jinesh Patel(Executive Officer, Director)in
BoardJohn Huysmans(Director)
Co-investorsBantam GroupC2 VenturesCaduceus Capital PartnersDIAKluz VenturesOverline+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolio908 DevicesNASDAQ: MASS
Portfolio news
latest coverage across their companies
Scitara · intelligence360.news · Jul 29, 2026
Octave · stocktitan.net · Jul 14, 2026
908 Devices · tradersunion.com · Jul 13, 2026
Elephas Biosciences · newmarketpitch.com · Jul 13, 2026
Kytopen · nationaltoday.com · Apr 10, 2026
Vizgen · intelligence360.news · Feb 2, 2026
Culture Biosciences · finsmes.com · Dec 16, 2025
Frequently asked questions
- What stage does Northpond Ventures invest at?
- Northpond Ventures invests at the Seed, Series A stages.
- What is Northpond Ventures's typical check size?
- Northpond Ventures typically writes checks of $100K – $5M.
- What sectors does Northpond Ventures focus on?
- Northpond Ventures focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Deep Tech, Energy, Hardware, Healthtech, Medical Devices, Sector Agnostic.
- Where is Northpond Ventures located?
- Northpond Ventures is headquartered in Bethesda, US.
- Does Northpond Ventures lead rounds?
- Northpond Ventures typically participates in rounds rather than leading them.
Images
Co-investors · 45
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Sandbox Industries is an investment firm that fosters innovation in the healthcare and insurance industries, partnering with corporate strategic investors as limited partners alongside financial investors and portfolio companies.
Echo Health Ventures is a strategic venture capital and growth equity investor that partners with health care companies to help build and scale their innovations nationally.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Flybridge Capital Partners is an early-stage venture capital firm that invests in entrepreneurs building companies with global reach. The firm focuses on supporting innovative ventures from their initial funding stages.
S32 is a high-conviction venture firm that concentrates on a small set of core relationships, committing deeply and supporting founders over the long term.
Deerfield Management is a healthcare-focused investment firm that supports companies across the healthcare ecosystem through flexible funding, market intelligence, and philanthropic initiatives.
The E14 Fund is an early-stage venture firm affiliated with MIT that invests in AI and deep-tech companies and runs an investment fellowship program for earlier-stage founders.
6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.
Genoa Ventures is a venture capital firm that works with strategic partners providing market insights, validated deal flow, and domain expertise to support its portfolio companies.
▶33 more co-investors
Vensana CapitalMerck Global Health Innovation FundBreakout VenturesFirst Round CapitalKleiner PerkinsSound VenturesStreamlined VenturesSusa VenturesInnovation EndeavorsSignalFireCrosslink CapitalMaveronM13Breakthrough Energy VenturesMMC VenturesBasementSRB VenturessequelSanofi VenturesAsset Management VenturesMechanism CapitalForesite CapitalCourtside VenturesTencent HoldingsaMoonDarco Capital4BIO CapitalSRI CapitalSharp AlphaGolden Seeds82VSGENERAL INCEPTIONOMX Ventures
Firms observed investing alongside Northpond Ventures, from public investor directories. Shared companies are the overlap with Northpond Ventures's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Qbic is an inter-university venture capital fund that turns technological breakthroughs from its partner universities, research institutes and hospitals into sustainable businesses.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner, backing emerging and established fund managers who invest in technology-focused Canadian companies.